U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's ILUVIEN® for Chronic Diabetic Macular Edema

   U.K.'s NICE Issues Final Appraisal Determination Recommending Alimera's
                 ILUVIEN® for Chronic Diabetic Macular Edema

  PR Newswire

  ATLANTA, Oct. 1, 2013

-- Recommendation will provide access to funding for a subgroup of chronic DME
patients

ATLANTA, Oct. 1, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that in its Final Appraisal Determination, the United
Kingdom's National Institute for Health and Care Excellence (NICE) has
recommended ILUVIEN funding for the treatment of pseudophakic eyes in chronic
diabetic macular edema (DME) patients that are insufficiently responsive to
available therapies.

The final draft guidance reverses the published guidance issued by NICE on
January 23, 2013, and takes into consideration a simple patient access scheme
submitted by Alimera. In addition, NICE reviewed Alimera's updated data
analysis showing ILUVIEN's cost effectiveness among a subgroup of chronic DME
patients who have an eye that is considered pseudophakic, meaning that the eye
has already undergone cataract surgery.

"I am very pleased that my chronic DME patients will soon have access through
the National Health Service (NHS) to ILUVIEN as a treatment option," said Mr.
Moin Mohamed, Consultant Ophthalmic Surgeon, Guy's and St Thomas' Hospital NHS
Foundation Trust, London. "Vision is precious and a major contributor to a
patient's overall quality of life. This recommendation from NICE gives chronic
pseudophakic DME patients, who have exhausted all other treatment options,
renewed hope. Ultimately, I would like to see ILUVIEN made available to all
people with chronic DME."

ILUVIEN, a sustained release intravitreal implant, has received marketing
authorization in the U.K., Austria, Portugal, Germany, France and Spain, and
is pending in Italy. ILUVIEN is currently commercially available in the U.K.
and Germany.

"The NICE recommendation is a welcome development for chronic DME patients
across England and Wales," said Mr. Robin Hamilton, Consultant Ophthalmic
Surgeon, Moorfields Eye Hospital NHS Foundation Trust, London. "With this
determination, these patients will have access through NHS to a long-term,
sustained release option for achieving improved visual acuity. ILUVIEN can
have a significantly positive impact on their lives."

"This is excellent news for Alimera, as this positive recommendation from NICE
will require the National Health Service (NHS) to make funding available for
ILUVIEN in England and Wales. We plan to continue to work with NICE in an
effort to broaden access to ILUVIEN to include all chronic DME patients who
could benefit from the treatment," said Dan Myers, Alimera's president and
chief executive officer.

NICE's final guidance regarding reimbursement of ILUVIEN within the NHS in
England and Wales is expected to be published in November 2013.

About ILUVIEN ^®

ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained
release intravitreal implant used to treat vision impairment associated with
chronic DME considered insufficiently responsive to available therapies. Each
ILUVIEN implant provides a therapeutic effect of up to 36 months by delivering
sustained sub-microgram levels of fluocinolone acetonide (FAc). ILUVIEN is
injected in the back of the patient's eye to a position that takes advantage
of the eye's natural fluid dynamics. The applicator employs a 25-gauge needle,
which allows for a self-sealing wound. In the FAME™ Study, the most frequently
reported adverse drug reactions included cataract development and increased
ocular pressure.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company that specializes in the research, development and
commercialization of prescription ophthalmic pharmaceuticals. Alimera's
European operations are conducted from London by its wholly-owned subsidiary,
Alimera Sciences Limited.

Forward Looking Statements

This press release contains "forward-looking statements," within the meaning
of the Private Securities Litigation Reform Act of 1995, regarding, among
other things, the extent of the commercial availability and funding of ILUVIEN
in the United Kingdom. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause actual results
to differ materially from those projected in its forward-looking statements.
Meaningful factors which could cause actual results to differ include, but are
not limited to NICE's acceptance of the recommendations contained in ACD,
uncertainty as to Alimera's ability to commercialize, and market acceptance
of, ILUVIEN in the United Kingdom, as well as other factors discussed in the
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Alimera's Annual Report on
Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form
10-Q for the quarter ended June 30, 2013, which are on file with the
Securities and Exchange Commission (SEC) and available on the SEC's website at
www.sec.gov . In addition to the risks described above and in Alimera's Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and other filings with the SEC, other unknown or unpredictable factors
also could affect Alimera's results. There can be no assurance that the actual
results or developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected consequences to, or
effects on, Alimera. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly
qualified by the cautionary statements contained or referred to herein.
Alimera cautions investors not to rely too heavily on the forward-looking
statements Alimera makes or that are made on its behalf. These forward-looking
statements speak only as of the date of this press release (unless another
date is indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such forward-looking
statements, whether as a result of new information, future events or
otherwise.

For press inquiries:            For investor inquiries:

Katie Brazel, Fleishman-Hillard John Mills, ICR

for Alimera Sciences            for Alimera Sciences

+1-404-739-0150                 +1-310-954-1105

Katie.Brazel@fleishman.com      John.Mills@ICRINC.com
 
Press spacebar to pause and continue. Press esc to stop.